Clinical experience with angiotensin II receptor antagonists

Détails

ID Serval
serval:BIB_6E7084855082
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Clinical experience with angiotensin II receptor antagonists
Périodique
American Journal of Hypertension
Auteur⸱e⸱s
Brunner  H. R., Christen  Y., Munafo  A., Lee  R. J., Waeber  B., Nussberger  J.
ISSN
0895-7061 (Print)
Statut éditorial
Publié
Date de publication
12/1992
Volume
5
Numéro
12 Pt 2
Pages
243S-246S
Notes
Clinical Trial
Controlled Clinical Trial
Journal Article --- Old month value: Dec
Résumé
This series of studies was designed to assess in normal volunteers the relationships between various doses (5, 10, 20, 40, 80, and 120 mg) of the orally active angiotensin II antagonist losartan (DuP 753, MK-954) and their inhibitory effect on the pressure response to a given bolus of angiotensin I or II. It was found that the maximal inhibitory effect was reached with a dose of 80 mg. The minimal dose necessary for maximal efficacy would therefore be expected to be between 40 and 80 mg. The effect lasted for more than 24 h and was related almost exclusively to the circulating levels of the active metabolite EXP3174. It remains to be demonstrated in hypertensive patients that the same dose relationship holds for the antihypertensive effect, but preliminary data already suggest that this is the case.
Mots-clé
Administration, Oral Angiotensin I/administration & dosage/pharmacology Angiotensin II/administration & dosage/antagonists & inhibitors/pharmacology Antihypertensive Agents/administration & dosage/adverse effects/therapeutic use Biphenyl Compounds/administration & dosage/adverse effects/*therapeutic use Blood Pressure/drug effects/physiology Dose-Response Relationship, Drug Humans Hypertension/blood/drug therapy/physiopathology Imidazoles/administration & dosage/adverse effects/blood/*therapeutic use Injections, Intravenous Losartan Receptors, Angiotensin/*antagonists & inhibitors Renin-Angiotensin System/drug effects/physiology Tetrazoles/administration & dosage/adverse effects/blood/*therapeutic use Time Factors
Pubmed
Web of science
Création de la notice
05/03/2008 16:41
Dernière modification de la notice
20/08/2019 14:27
Données d'usage